Download PDFPDF

Acetylcholinesterase inhibition with pyridostigmine improves heart rate recovery after maximal exercise in patients with chronic heart failure
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Pyridostigmine in CHF: Author's Response to Dr. Nobrega

    Dear Editor

    We greatly appreciate Dr Nobrega’s interest in our recent publication on the acute effects of pyridostigmine on post-exercise heart rate recovery in patients with chronic heart failure.[1]

    In accord with our published submaximal exercise data at anaerobic threshold, our more complete analysis of submaximal exercise demonstrated no differences between the effects of pyridostigmine 30 mg and pl...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Cholinergic stimulation in chronic heart failure: modifiyng predictors of risk

    Dear Editor

    The article by Androne et al.[1] describing the improvement in heart rate recovery after maximal exercise in patients with chronic heart failure when treated with pyridostigmine, supports the recent concept that cholinergic stimulation may have a protective role in cardiovascular disease.[2] We have prompted to investigate this possibility, since depressed heart rate variability[3] and baroref...

    Show More
    Conflict of Interest:
    None declared.